DR. REDDY'S LABORATORIES-ADR (RDY) Fundamental Analysis & Valuation
NYSE:RDY • US2561352038
Current stock price
13.16 USD
-0.16 (-1.2%)
Last:
This RDY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RDY Profitability Analysis
1.1 Basic Checks
- RDY had positive earnings in the past year.
- RDY had a positive operating cash flow in the past year.
- In the past 5 years RDY has always been profitable.
- In the past 5 years RDY always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 10.62%, RDY belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
- With an excellent Return On Equity value of 16.03%, RDY belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
- RDY has a better Return On Invested Capital (13.03%) than 91.67% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for RDY is above the industry average of 13.06%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| ROIC | 13.03% |
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
1.3 Margins
- RDY has a Profit Margin of 16.82%. This is amongst the best in the industry. RDY outperforms 89.06% of its industry peers.
- In the last couple of years the Profit Margin of RDY has grown nicely.
- The Operating Margin of RDY (19.62%) is better than 87.50% of its industry peers.
- RDY's Operating Margin has improved in the last couple of years.
- RDY has a Gross Margin of 66.88%. This is in the better half of the industry: RDY outperforms 75.00% of its industry peers.
- RDY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.62% | ||
| PM (TTM) | 16.82% | ||
| GM | 66.88% |
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
2. RDY Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so RDY is still creating some value.
- RDY has about the same amout of shares outstanding than it did 1 year ago.
- RDY has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for RDY is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 5.62 indicates that RDY is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.62, RDY is in the better half of the industry, outperforming 78.13% of the companies in the same industry.
- The Debt to FCF ratio of RDY is 3.17, which is a good value as it means it would take RDY, 3.17 years of fcf income to pay off all of its debts.
- RDY's Debt to FCF ratio of 3.17 is amongst the best of the industry. RDY outperforms 90.10% of its industry peers.
- RDY has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.03, RDY is in line with its industry, outperforming 54.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 3.17 | ||
| Altman-Z | 5.62 |
ROIC/WACC1.29
WACC10.13%
2.3 Liquidity
- RDY has a Current Ratio of 1.85. This is a normal value and indicates that RDY is financially healthy and should not expect problems in meeting its short term obligations.
- RDY's Current ratio of 1.85 is on the low side compared to the rest of the industry. RDY is outperformed by 65.63% of its industry peers.
- RDY has a Quick Ratio of 1.35. This is a normal value and indicates that RDY is financially healthy and should not expect problems in meeting its short term obligations.
- RDY's Quick ratio of 1.35 is on the low side compared to the rest of the industry. RDY is outperformed by 69.27% of its industry peers.
- RDY does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.35 |
3. RDY Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 3.81% over the past year.
- RDY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 23.62% yearly.
- RDY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.06%.
- RDY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.26% yearly.
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%
3.2 Future
- The Earnings Per Share is expected to decrease by -1.22% on average over the next years.
- Based on estimates for the next years, RDY will show a small growth in Revenue. The Revenue will grow by 6.56% on average per year.
EPS Next Y-7.04%
EPS Next 2Y-8.78%
EPS Next 3Y-1.22%
EPS Next 5YN/A
Revenue Next Year6.78%
Revenue Next 2Y4.98%
Revenue Next 3Y6.48%
Revenue Next 5Y6.56%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. RDY Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 18.28, RDY is valued on the expensive side.
- Compared to the rest of the industry, the Price/Earnings ratio of RDY indicates a rather cheap valuation: RDY is cheaper than 83.85% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.17, RDY is valued a bit cheaper.
- The Price/Forward Earnings ratio is 21.70, which indicates a rather expensive current valuation of RDY.
- 76.56% of the companies in the same industry are more expensive than RDY, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of RDY to the average of the S&P500 Index (23.05), we can say RDY is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.28 | ||
| Fwd PE | 21.7 |
4.2 Price Multiples
- 85.42% of the companies in the same industry are more expensive than RDY, based on the Enterprise Value to EBITDA ratio.
- RDY's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. RDY is cheaper than 77.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.22 | ||
| EV/EBITDA | 11.03 |
4.3 Compensation for Growth
- RDY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.77
EPS Next 2Y-8.78%
EPS Next 3Y-1.22%
5. RDY Dividend Analysis
5.1 Amount
- With a yearly dividend of 0.62%, RDY is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 0.64, RDY pays a better dividend. On top of this RDY pays more dividend than 89.06% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.89, RDY's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.62% |
5.2 History
- The dividend of RDY decreases each year by -19.44%.
- RDY has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-19.44%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- RDY pays out 11.54% of its income as dividend. This is a sustainable payout ratio.
- RDY's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP11.54%
EPS Next 2Y-8.78%
EPS Next 3Y-1.22%
RDY Fundamentals: All Metrics, Ratios and Statistics
NYSE:RDY (4/6/2026, 11:56:09 AM)
13.16
-0.16 (-1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21 2026-01-21/amc
Earnings (Next)05-07 2026-05-07/amc
Inst Owners52.01%
Inst Owner Change0%
Ins Owners1.23%
Ins Owner Change0%
Market Cap10.96B
Revenue(TTM)346.82B
Net Income(TTM)57.72B
Analysts67.56
Price Target15.24 (15.81%)
Short Float %2.34%
Short Ratio6.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.62% |
Yearly Dividend0.09
Dividend Growth(5Y)-19.44%
DP11.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.63%
Min EPS beat(2)-8.52%
Max EPS beat(2)-6.74%
EPS beat(4)1
Avg EPS beat(4)-3.93%
Min EPS beat(4)-8.52%
Max EPS beat(4)2.77%
EPS beat(8)4
Avg EPS beat(8)-0.94%
EPS beat(12)8
Avg EPS beat(12)6.66%
EPS beat(16)10
Avg EPS beat(16)7.01%
Revenue beat(2)0
Avg Revenue beat(2)-2.69%
Min Revenue beat(2)-3.88%
Max Revenue beat(2)-1.51%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-3.88%
Max Revenue beat(4)1%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)7
Avg Revenue beat(12)1.24%
Revenue beat(16)9
Avg Revenue beat(16)1.2%
PT rev (1m)0%
PT rev (3m)2.13%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)-3.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.94%
Revenue NQ rev (1m)-0.43%
Revenue NQ rev (3m)-1.38%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)1.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.28 | ||
| Fwd PE | 21.7 | ||
| P/S | 2.97 | ||
| P/FCF | 55.22 | ||
| P/OCF | 17.34 | ||
| P/B | 2.83 | ||
| P/tB | 4.16 | ||
| EV/EBITDA | 11.03 |
EPS(TTM)0.72
EY5.47%
EPS(NY)0.61
Fwd EY4.61%
FCF(TTM)0.24
FCFY1.81%
OCF(TTM)0.76
OCFY5.77%
SpS4.43
BVpS4.65
TBVpS3.16
PEG (NY)N/A
PEG (5Y)0.77
Graham Number8.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| ROCE | 17.14% | ||
| ROIC | 13.03% | ||
| ROICexc | 16.05% | ||
| ROICexgc | 25.11% | ||
| OM | 19.62% | ||
| PM (TTM) | 16.82% | ||
| GM | 66.88% | ||
| FCFM | 5.38% |
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
ROICexc(3y)19.62%
ROICexc(5y)17.62%
ROICexgc(3y)25.36%
ROICexgc(5y)22.59%
ROCE(3y)21.22%
ROCE(5y)19.86%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y2.58%
ROICexc growth 3Y0.6%
ROICexc growth 5Y-0.12%
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
F-Score4
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 3.17 | ||
| Debt/EBITDA | 0.13 | ||
| Cap/Depr | 211.61% | ||
| Cap/Sales | 11.76% | ||
| Interest Coverage | 16.55 | ||
| Cash Conversion | 68.09% | ||
| Profit Quality | 32% | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.62 |
F-Score4
WACC10.13%
ROIC/WACC1.29
Cap/Depr(3y)179.81%
Cap/Depr(5y)161.03%
Cap/Sales(3y)9.33%
Cap/Sales(5y)8.68%
Profit Quality(3y)47.43%
Profit Quality(5y)60.48%
High Growth Momentum
Growth
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
EPS Next Y-7.04%
EPS Next 2Y-8.78%
EPS Next 3Y-1.22%
EPS Next 5YN/A
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%
Revenue Next Year6.78%
Revenue Next 2Y4.98%
Revenue Next 3Y6.48%
Revenue Next 5Y6.56%
EBIT growth 1Y1.53%
EBIT growth 3Y25.68%
EBIT growth 5Y18.58%
EBIT Next Year11.9%
EBIT Next 3Y6.94%
EBIT Next 5Y9.33%
FCF growth 1Y-62.42%
FCF growth 3Y9.92%
FCF growth 5Y-12.7%
OCF growth 1Y-18.43%
OCF growth 3Y18.21%
OCF growth 5Y9.24%
DR. REDDY'S LABORATORIES-ADR / RDY Fundamental Analysis FAQ
What is the ChartMill fundamental rating of DR. REDDY'S LABORATORIES-ADR (RDY) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RDY.
What is the valuation status for RDY stock?
ChartMill assigns a valuation rating of 5 / 10 to DR. REDDY'S LABORATORIES-ADR (RDY). This can be considered as Fairly Valued.
How profitable is DR. REDDY'S LABORATORIES-ADR (RDY) stock?
DR. REDDY'S LABORATORIES-ADR (RDY) has a profitability rating of 8 / 10.
What are the PE and PB ratios of DR. REDDY'S LABORATORIES-ADR (RDY) stock?
The Price/Earnings (PE) ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 18.28 and the Price/Book (PB) ratio is 2.83.
How financially healthy is DR. REDDY'S LABORATORIES-ADR?
The financial health rating of DR. REDDY'S LABORATORIES-ADR (RDY) is 6 / 10.